With the increasing availability of anti-cancer drugs, the critical role of immune cells in cancer therapy has been validated, and adoptive cell therapies are more frequently a treatment of choice.
A number of challenges remain in the manufacture of these therapies, especially as we look to move to commercial-scale production. These challenges have caused industry participants to express concerns that the manufacturing shortage would threaten industry growth and lengthen time-to-market for these living therapies.
Upscaling and streamline manufacturing processes are key to ensure future successes in the clinic. In this webinar, we will introduce Miltenyi Biotec’s solutions and discuss the generation of gene-modified CAR-T and CAR NK cells in a standardized and fully automated fashion with academic and industry end user panellists.